Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ionotropic glutamate receptor AMPA-type subunits (GluA1-4) are the primary mediators of fast excitatory synaptic transmission in the mammalian central nervous system [1.2.1, 1.4.4]. These receptors are tetrameric assemblies of four subunits that form a ligand-gated ion channel, which opens in response to the binding of the neurotransmitter glutamate to allow the influx of cations like sodium and calcium [1.2.1, 1.5.1]. AMPA receptors play a critical role in synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), which are the cellular foundations of learning and memory [1.1.3, 1.2.2]. Dysregulation of AMPA receptor function is implicated in a wide range of neurological and psychiatric disorders, including epilepsy, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) [1.2.1, 1.5.2]. Pharmacological targeting of these receptors includes non-competitive antagonists like perampanel for seizure control and positive allosteric modulators (ampakines) being investigated for cognitive enhancement [1.3.3, 1.5.3]. However, therapeutic use is often limited by safety concerns such as sedation, ataxia, and potential for excitotoxicity or proconvulsive effects [1.5.3, 1.5.4]. The subunit composition, particularly the presence of the edited GluA2 subunit, determines the calcium permeability and overall signaling properties of the receptor complex [1.2.4, 1.4.4]. Recent research also highlights their role in conditions like long COVID-associated brain fog and chronic pain [1.1.1, 1.1.4].
Non-competitive antagonism, competitive antagonism, positive allosteric modulation, and negative allosteric modulation of the ion channel pore or ligand-binding domain.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ionotropic glutamate receptor AMPA-type subunits (AMPAR).